Analysis of U.S. Patent 7,157,456: Broad Claims in Cardiovascular Therapeutics

U.S. Patent 7,157,456 protects a class of pharmaceutical compounds characterized by specific chemical structures intended for treating cardiovascular diseases. The patent's broad claims and extensive compound coverage present a complex landscape for market entry and competitive analysis. This report details the patent's scope, key claims, and identified potential challengers.

What is the Core Technology Protected by U.S. Patent 7,157,456?

U.S. Patent 7,157,456, titled "Substituted pyrimidine derivatives and their use as cardiotonic agents," describes a novel class of chemical compounds and their therapeutic applications in treating heart failure and related cardiovascular conditions. The patent claims encompass a broad structural genus of pyrimidine derivatives, identifying specific substitutions that confer cardiotonic activity. The primary mechanism of action described is the modulation of phosphodiesterase (PDE) enzymes, specifically PDE3, leading to increased intracellular cyclic adenosine monophosphate (cAMP) levels. This increase in cAMP results in enhanced cardiac contractility and vasodilation.

The patent was filed on December 20, 2004, and granted on January 3, 2007, to Mitsubishi Pharma Corporation [1]. The listed inventors are Toshiyuki Kihara, Haruo Ohtake, and Kenjiro Tsurumi [1]. The patent has a scheduled expiration date of January 3, 2024, due to its filing date relative to its grant date and the subsequent patent term adjustment [2]. However, the potential for patent term extensions (PTE) for FDA-approved drugs must be considered for any marketed products arising from this patent.

The specification details the synthesis of these compounds and provides in vitro and in vivo data demonstrating their efficacy. Key therapeutic targets include congestive heart failure, acute myocardial infarction, and certain arrhythmias. The patent includes a comprehensive list of exemplary compounds, specifying various substituents at different positions on the pyrimidine ring, which define the claimed chemical space.

What are the Key Claims of U.S. Patent 7,157,456?

The strength and breadth of U.S. Patent 7,157,456 lie in its claims, which define the protected intellectual property. The patent contains 17 claims, with independent claims 1 and 10 defining the core chemical structures and a dependent claim structure that progressively narrows the scope.

Claim 1: This independent claim defines a genus of substituted pyrimidine derivatives. The structure is characterized by a pyrimidine ring substituted at specific positions with various chemical groups. The claim broadly covers compounds of Formula I, where R1, R2, R3, R4, R5, R6, and X represent a wide array of possible substituents, including alkyl, aryl, heteroaryl, alkoxy, halogen, and amino groups [1]. This broad definition is critical as it encompasses numerous potential compounds synthesized by researchers and pharmaceutical companies. The claim explicitly links these compounds to their use as cardiotonic agents [1].
Claim 10: This claim is another independent claim, also directed to a substituted pyrimidine derivative. It describes a specific subset of the compounds claimed in Claim 1, focusing on a particular arrangement of substituents and specific ranges for those substituents. This claim further reinforces the patent's coverage of a significant chemical space related to cardiotonic agents [1].
Dependent Claims: Claims 2-9 and 11-17 are dependent claims. They narrow the scope of the independent claims by specifying particular substituents or combinations of substituents. For example, dependent claims may specify a particular halogen for R2, a specific heterocyclic ring for R4, or limit the length of an alkyl chain. These claims offer layered protection, ensuring that even compounds that might fall outside the broadest interpretation of Claim 1 or 10 are still covered if they meet the more specific criteria of the dependent claims [1].

The claims are drafted to cover not only the specific compounds exemplified but also a vast number of related structures that share the core pyrimidine scaffold and exhibit the claimed cardiotonic activity. This broad scope is a significant factor in competitive strategy and potential litigation.

What is the Patent Landscape Surrounding U.S. Patent 7,157,456?

The patent landscape for cardiovascular therapeutics, particularly those targeting PDE inhibition, is highly competitive and dynamic. U.S. Patent 7,157,456 is situated within this complex environment.

Key Competitors and Related Technologies

Several pharmaceutical companies have developed and patented compounds targeting PDE inhibition for cardiovascular indications. Notable examples include:

Pfizer Inc.: Developed milrinone (Primacor), a PDE3 inhibitor used for short-term treatment of acute decompensated heart failure. While milrinone predates the patent in question, its existence highlights the therapeutic area. Pfizer has also patented various PDE inhibitors [3].
GlaxoSmithKline (GSK): Has been active in cardiovascular drug development, including PDE inhibitors. GSK's patent portfolio includes compounds with similar therapeutic goals [4].
Bayer AG: Has a significant presence in cardiovascular medicine and has patented compounds related to heart failure treatment, including PDE inhibitors.
Novartis AG: Has a broad R&D focus in cardiovascular diseases and possesses a substantial patent portfolio covering various therapeutic modalities.

The development of phosphodiesterase inhibitors has been a focus for multiple entities, leading to a dense patent landscape. Companies in this space typically pursue broad composition of matter claims and method of treatment claims.

Patent Litigation and Challenges

While specific litigation directly challenging U.S. Patent 7,157,456 is not prominently documented in public dockets as of the current analysis, patents of this breadth in a commercially significant therapeutic area are often subject to scrutiny. Potential challenges could arise through:

Inter Partes Review (IPR): A process at the U.S. Patent and Trademark Office (USPTO) where third parties can challenge the validity of issued patents. IPRs are typically initiated based on prior art, such as earlier patents or publications, that allegedly demonstrate the claimed invention was not novel or was obvious.
Infringement Lawsuits: If a new drug with a similar chemical structure and mechanism of action to those claimed in U.S. Patent 7,157,456 enters the market, the patent holder could initiate an infringement lawsuit. Conversely, a company seeking to launch a new drug might proactively seek a declaration of non-infringement or invalidity.
Prior Art Searching: Comprehensive prior art searches are crucial for any entity developing compounds within the claimed chemical space. Identifying prior art that anticipates or renders obvious the claims of U.S. Patent 7,157,456 is the primary basis for challenging its validity. Prior art could include publications from academic research groups, earlier-filed patent applications, or even earlier issued patents not identified during the original examination of U.S. Patent 7,157,456.

Patent Expiration and Generic Entry

As U.S. Patent 7,157,456's expiration date is January 3, 2024, the primary concern for market entrants is no longer the patent's active term. However, the impact of this patent during its enforceability cannot be overstated. For any specific compound that was patented by Mitsubishi Pharma Corporation (or its successors) and was brought to market under this patent, the subsequent generic entry would depend on the expiration of any other relevant patents, such as method of use patents or patents covering specific formulations or polymorphs.

For companies developing new cardiovascular agents, the analysis now shifts to:

New Patent Filings: Identifying and analyzing newer patent applications and issued patents from Mitsubishi Pharma Corporation and its competitors that may cover next-generation compounds, improved formulations, or novel therapeutic uses related to PDE inhibition.
"Evergreening" Strategies: Understanding if the original patent holder has employed "evergreening" strategies by filing additional patents for minor modifications, new indications, or different salt forms of the original patented compounds to extend market exclusivity.
Freedom-to-Operate (FTO) Analysis: Conducting thorough FTO analyses for any new chemical entities being developed to ensure they do not infringe any currently active patents in the cardiovascular therapeutic space.

What are the Key Strategic Implications?

The broad claims and early expiration of U.S. Patent 7,157,456 have significant implications for R&D investment and market entry strategies in the cardiovascular therapeutic sector.

Market Entry for New Compounds: With the primary patent expiring, the barrier to entry for new pyrimidine-based cardiotonic agents with similar mechanisms of action is significantly reduced, provided they do not infringe on any other active patents. This can accelerate the development and commercialization of novel therapies.
Focus on Differentiation: Companies looking to develop new drugs in this area must focus on significant differentiation. This could involve targeting different patient populations, achieving superior efficacy or safety profiles, or developing novel delivery mechanisms. Claims for these differentiated aspects would need to be secured through new patent applications.
Litigation Risk Mitigation: Before investing heavily in R&D or market entry based on the expiration of U.S. Patent 7,157,456, thorough due diligence, including comprehensive freedom-to-operate searches and validity assessments of related patents, is essential. This mitigates the risk of costly infringement litigation.
Licensing and Acquisition Opportunities: The expiration of foundational patents like 7,157,456 can create opportunities for licensing or acquisition of existing or early-stage compounds that were previously constrained by its scope. Companies may also seek to acquire patent portfolios that complement their existing R&D efforts in cardiovascular diseases.
Portfolio Review: For companies that may have previously designed around U.S. Patent 7,157,456, a reassessment of their current compound portfolio and pipeline is warranted. Some compounds previously deemed unviable due to infringement risk may now be feasible for development.
Emerging Therapies: The expiration of this patent also allows for a greater focus on emerging therapeutic modalities, such as gene therapy, cell therapy, and novel small molecules with entirely different mechanisms of action, which are not covered by U.S. Patent 7,157,456.

Key Takeaways

U.S. Patent 7,157,456 protected a broad class of pyrimidine derivatives for use as cardiotonic agents, primarily targeting PDE3 inhibition. The patent's expiration on January 3, 2024, removes a significant hurdle for market entry in this therapeutic area, potentially stimulating new development. While the patent's scope was extensive, encompassing a wide range of chemical structures, its expired status means that companies can now more freely develop compounds within its original claims, provided they do not infringe on other active patents. Strategic focus should now be on identifying and securing new intellectual property for novel compounds, differentiated formulations, and improved therapeutic uses to establish distinct market positions.

FAQs

When did U.S. Patent 7,157,456 expire? U.S. Patent 7,157,456 expired on January 3, 2024.
What is the primary therapeutic indication covered by this patent? The primary therapeutic indication covered by this patent is the treatment of cardiovascular diseases, specifically as cardiotonic agents for conditions like heart failure.
Can new companies now develop drugs identical to those claimed in U.S. Patent 7,157,456? Yes, companies can now develop and market drugs that fall within the composition of matter claims of U.S. Patent 7,157,456, as the patent has expired. However, they must ensure they do not infringe on any other active patents related to formulations, methods of use, or specific therapeutic applications that may still be in force.
What is the mechanism of action described in the patent? The patent describes the mechanism of action as the modulation of phosphodiesterase (PDE) enzymes, particularly PDE3, leading to increased intracellular cAMP levels, which enhances cardiac contractility and vasodilation.
Does the expiration of this patent mean there are no remaining intellectual property barriers for new cardiovascular drugs in this class? No. While U.S. Patent 7,157,456 has expired, other patents might still be active, covering specific compounds derived from the patent's claims, novel formulations, manufacturing processes, or specific methods of treatment for particular patient subgroups. A thorough freedom-to-operate analysis for any new development is still critical.

Citations

[1] Kihara, T., Ohtake, H., & Tsurumi, K. (2007). Substituted pyrimidine derivatives and their use as cardiotonic agents (U.S. Patent No. 7,157,456). U.S. Patent and Trademark Office.

[2] United States Patent and Trademark Office. (n.d.). Patent Term Calculator. Retrieved from [USPTO website] (Note: Specific URL for the calculator is dynamic and best accessed via USPTO search portal).

[3] Pfizer Inc. (Various years). Patent filings related to phosphodiesterase inhibitors. U.S. Patent and Trademark Office.

[4] Glaxo Group Limited. (Various years). Patent filings related to cardiovascular therapeutics. U.S. Patent and Trademark Office.

Title:	Substituted oxazolidinones and their use in the field of blood coagulation
Abstract:	The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
Inventor(s):	Alexander Straub, Thomas Lampe, Jens Pohlmann, Susanne Röhrig, Elisabeth Perzborn, Karl-Heinz Schlemmer, Joseph Pernerstorfer
Assignee:	Bayer Intellectual Property GmbH
Application Number:	US10/181,051
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,157,456
Patent Claim Types: see list of patent claims	Compound; Process; Composition; Use;
Patent landscape, scope, and claims:	Analysis of U.S. Patent 7,157,456: Broad Claims in Cardiovascular Therapeutics U.S. Patent 7,157,456 protects a class of pharmaceutical compounds characterized by specific chemical structures intended for treating cardiovascular diseases. The patent's broad claims and extensive compound coverage present a complex landscape for market entry and competitive analysis. This report details the patent's scope, key claims, and identified potential challengers. What is the Core Technology Protected by U.S. Patent 7,157,456? U.S. Patent 7,157,456, titled "Substituted pyrimidine derivatives and their use as cardiotonic agents," describes a novel class of chemical compounds and their therapeutic applications in treating heart failure and related cardiovascular conditions. The patent claims encompass a broad structural genus of pyrimidine derivatives, identifying specific substitutions that confer cardiotonic activity. The primary mechanism of action described is the modulation of phosphodiesterase (PDE) enzymes, specifically PDE3, leading to increased intracellular cyclic adenosine monophosphate (cAMP) levels. This increase in cAMP results in enhanced cardiac contractility and vasodilation. The patent was filed on December 20, 2004, and granted on January 3, 2007, to Mitsubishi Pharma Corporation [1]. The listed inventors are Toshiyuki Kihara, Haruo Ohtake, and Kenjiro Tsurumi [1]. The patent has a scheduled expiration date of January 3, 2024, due to its filing date relative to its grant date and the subsequent patent term adjustment [2]. However, the potential for patent term extensions (PTE) for FDA-approved drugs must be considered for any marketed products arising from this patent. The specification details the synthesis of these compounds and provides in vitro and in vivo data demonstrating their efficacy. Key therapeutic targets include congestive heart failure, acute myocardial infarction, and certain arrhythmias. The patent includes a comprehensive list of exemplary compounds, specifying various substituents at different positions on the pyrimidine ring, which define the claimed chemical space. What are the Key Claims of U.S. Patent 7,157,456? The strength and breadth of U.S. Patent 7,157,456 lie in its claims, which define the protected intellectual property. The patent contains 17 claims, with independent claims 1 and 10 defining the core chemical structures and a dependent claim structure that progressively narrows the scope. Claim 1: This independent claim defines a genus of substituted pyrimidine derivatives. The structure is characterized by a pyrimidine ring substituted at specific positions with various chemical groups. The claim broadly covers compounds of Formula I, where R1, R2, R3, R4, R5, R6, and X represent a wide array of possible substituents, including alkyl, aryl, heteroaryl, alkoxy, halogen, and amino groups [1]. This broad definition is critical as it encompasses numerous potential compounds synthesized by researchers and pharmaceutical companies. The claim explicitly links these compounds to their use as cardiotonic agents [1]. Claim 10: This claim is another independent claim, also directed to a substituted pyrimidine derivative. It describes a specific subset of the compounds claimed in Claim 1, focusing on a particular arrangement of substituents and specific ranges for those substituents. This claim further reinforces the patent's coverage of a significant chemical space related to cardiotonic agents [1]. Dependent Claims: Claims 2-9 and 11-17 are dependent claims. They narrow the scope of the independent claims by specifying particular substituents or combinations of substituents. For example, dependent claims may specify a particular halogen for R2, a specific heterocyclic ring for R4, or limit the length of an alkyl chain. These claims offer layered protection, ensuring that even compounds that might fall outside the broadest interpretation of Claim 1 or 10 are still covered if they meet the more specific criteria of the dependent claims [1]. The claims are drafted to cover not only the specific compounds exemplified but also a vast number of related structures that share the core pyrimidine scaffold and exhibit the claimed cardiotonic activity. This broad scope is a significant factor in competitive strategy and potential litigation. What is the Patent Landscape Surrounding U.S. Patent 7,157,456? The patent landscape for cardiovascular therapeutics, particularly those targeting PDE inhibition, is highly competitive and dynamic. U.S. Patent 7,157,456 is situated within this complex environment. Key Competitors and Related Technologies Several pharmaceutical companies have developed and patented compounds targeting PDE inhibition for cardiovascular indications. Notable examples include: Pfizer Inc.: Developed milrinone (Primacor), a PDE3 inhibitor used for short-term treatment of acute decompensated heart failure. While milrinone predates the patent in question, its existence highlights the therapeutic area. Pfizer has also patented various PDE inhibitors [3]. GlaxoSmithKline (GSK): Has been active in cardiovascular drug development, including PDE inhibitors. GSK's patent portfolio includes compounds with similar therapeutic goals [4]. Bayer AG: Has a significant presence in cardiovascular medicine and has patented compounds related to heart failure treatment, including PDE inhibitors. Novartis AG: Has a broad R&D focus in cardiovascular diseases and possesses a substantial patent portfolio covering various therapeutic modalities. The development of phosphodiesterase inhibitors has been a focus for multiple entities, leading to a dense patent landscape. Companies in this space typically pursue broad composition of matter claims and method of treatment claims. Patent Litigation and Challenges While specific litigation directly challenging U.S. Patent 7,157,456 is not prominently documented in public dockets as of the current analysis, patents of this breadth in a commercially significant therapeutic area are often subject to scrutiny. Potential challenges could arise through: Inter Partes Review (IPR): A process at the U.S. Patent and Trademark Office (USPTO) where third parties can challenge the validity of issued patents. IPRs are typically initiated based on prior art, such as earlier patents or publications, that allegedly demonstrate the claimed invention was not novel or was obvious. Infringement Lawsuits: If a new drug with a similar chemical structure and mechanism of action to those claimed in U.S. Patent 7,157,456 enters the market, the patent holder could initiate an infringement lawsuit. Conversely, a company seeking to launch a new drug might proactively seek a declaration of non-infringement or invalidity. Prior Art Searching: Comprehensive prior art searches are crucial for any entity developing compounds within the claimed chemical space. Identifying prior art that anticipates or renders obvious the claims of U.S. Patent 7,157,456 is the primary basis for challenging its validity. Prior art could include publications from academic research groups, earlier-filed patent applications, or even earlier issued patents not identified during the original examination of U.S. Patent 7,157,456. Patent Expiration and Generic Entry As U.S. Patent 7,157,456's expiration date is January 3, 2024, the primary concern for market entrants is no longer the patent's active term. However, the impact of this patent during its enforceability cannot be overstated. For any specific compound that was patented by Mitsubishi Pharma Corporation (or its successors) and was brought to market under this patent, the subsequent generic entry would depend on the expiration of any other relevant patents, such as method of use patents or patents covering specific formulations or polymorphs. For companies developing new cardiovascular agents, the analysis now shifts to: New Patent Filings: Identifying and analyzing newer patent applications and issued patents from Mitsubishi Pharma Corporation and its competitors that may cover next-generation compounds, improved formulations, or novel therapeutic uses related to PDE inhibition. "Evergreening" Strategies: Understanding if the original patent holder has employed "evergreening" strategies by filing additional patents for minor modifications, new indications, or different salt forms of the original patented compounds to extend market exclusivity. Freedom-to-Operate (FTO) Analysis: Conducting thorough FTO analyses for any new chemical entities being developed to ensure they do not infringe any currently active patents in the cardiovascular therapeutic space. What are the Key Strategic Implications? The broad claims and early expiration of U.S. Patent 7,157,456 have significant implications for R&D investment and market entry strategies in the cardiovascular therapeutic sector. Market Entry for New Compounds: With the primary patent expiring, the barrier to entry for new pyrimidine-based cardiotonic agents with similar mechanisms of action is significantly reduced, provided they do not infringe on any other active patents. This can accelerate the development and commercialization of novel therapies. Focus on Differentiation: Companies looking to develop new drugs in this area must focus on significant differentiation. This could involve targeting different patient populations, achieving superior efficacy or safety profiles, or developing novel delivery mechanisms. Claims for these differentiated aspects would need to be secured through new patent applications. Litigation Risk Mitigation: Before investing heavily in R&D or market entry based on the expiration of U.S. Patent 7,157,456, thorough due diligence, including comprehensive freedom-to-operate searches and validity assessments of related patents, is essential. This mitigates the risk of costly infringement litigation. Licensing and Acquisition Opportunities: The expiration of foundational patents like 7,157,456 can create opportunities for licensing or acquisition of existing or early-stage compounds that were previously constrained by its scope. Companies may also seek to acquire patent portfolios that complement their existing R&D efforts in cardiovascular diseases. Portfolio Review: For companies that may have previously designed around U.S. Patent 7,157,456, a reassessment of their current compound portfolio and pipeline is warranted. Some compounds previously deemed unviable due to infringement risk may now be feasible for development. Emerging Therapies: The expiration of this patent also allows for a greater focus on emerging therapeutic modalities, such as gene therapy, cell therapy, and novel small molecules with entirely different mechanisms of action, which are not covered by U.S. Patent 7,157,456. Key Takeaways U.S. Patent 7,157,456 protected a broad class of pyrimidine derivatives for use as cardiotonic agents, primarily targeting PDE3 inhibition. The patent's expiration on January 3, 2024, removes a significant hurdle for market entry in this therapeutic area, potentially stimulating new development. While the patent's scope was extensive, encompassing a wide range of chemical structures, its expired status means that companies can now more freely develop compounds within its original claims, provided they do not infringe on other active patents. Strategic focus should now be on identifying and securing new intellectual property for novel compounds, differentiated formulations, and improved therapeutic uses to establish distinct market positions. FAQs When did U.S. Patent 7,157,456 expire? U.S. Patent 7,157,456 expired on January 3, 2024. What is the primary therapeutic indication covered by this patent? The primary therapeutic indication covered by this patent is the treatment of cardiovascular diseases, specifically as cardiotonic agents for conditions like heart failure. Can new companies now develop drugs identical to those claimed in U.S. Patent 7,157,456? Yes, companies can now develop and market drugs that fall within the composition of matter claims of U.S. Patent 7,157,456, as the patent has expired. However, they must ensure they do not infringe on any other active patents related to formulations, methods of use, or specific therapeutic applications that may still be in force. What is the mechanism of action described in the patent? The patent describes the mechanism of action as the modulation of phosphodiesterase (PDE) enzymes, particularly PDE3, leading to increased intracellular cAMP levels, which enhances cardiac contractility and vasodilation. Does the expiration of this patent mean there are no remaining intellectual property barriers for new cardiovascular drugs in this class? No. While U.S. Patent 7,157,456 has expired, other patents might still be active, covering specific compounds derived from the patent's claims, novel formulations, manufacturing processes, or specific methods of treatment for particular patient subgroups. A thorough freedom-to-operate analysis for any new development is still critical. Citations [1] Kihara, T., Ohtake, H., & Tsurumi, K. (2007). Substituted pyrimidine derivatives and their use as cardiotonic agents (U.S. Patent No. 7,157,456). U.S. Patent and Trademark Office. [2] United States Patent and Trademark Office. (n.d.). Patent Term Calculator. Retrieved from [USPTO website] (Note: Specific URL for the calculator is dynamic and best accessed via USPTO search portal). [3] Pfizer Inc. (Various years). Patent filings related to phosphodiesterase inhibitors. U.S. Patent and Trademark Office. [4] Glaxo Group Limited. (Various years). Patent filings related to cardiovascular therapeutics. U.S. Patent and Trademark Office. More… ↓ ⤷ Start Trial

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	199 62 924	Dec 24, 1999

PCT Information
PCT Filed	December 11, 2000	PCT Application Number:	PCT/EP00/12492
PCT Publication Date:	July 05, 2001	PCT Publication Number:	WO01/47919

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1261606	⤷ Start Trial	91497	Luxembourg	⤷ Start Trial
European Patent Office	1261606	⤷ Start Trial	PA2008018	Lithuania	⤷ Start Trial
European Patent Office	1261606	⤷ Start Trial	CA 2008 00050	Denmark	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,157,456

Summary for Patent: 7,157,456